C Lebrun
Overview
Explore the profile of C Lebrun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
798
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michel M, Le Page E, Laplaud D, Wardi R, Lebrun C, Zagnoli F, et al.
Rev Neurol (Paris)
. 2021 Oct;
178(3):241-248.
PMID: 34598781
Background: Studies have shown that oral high-dose methylprednisolone (MP) is non-inferior to intravenous MP in treating multiple sclerosis relapses in terms of effectiveness and tolerance. In order to assist with...
2.
Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, et al.
Mult Scler
. 2020 Feb;
27(2):232-238.
PMID: 32077365
Background: Atypical myelitis in multiple sclerosis (MS) is characterized by extensive myelitis in the longitudinal (longitudinally extensive transverse myelitis) or axial plane (transverse myelitis). Objective: To characterize a cohort of...
3.
Lebrun C, Vukusic S
Rev Neurol (Paris)
. 2019 May;
175(6):341-357.
PMID: 31036391
Objectives: To establish recommendations on immunization for patients with multiple sclerosis (MS). Background: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the...
4.
Lebrun C, Bertagna M, Bresch S, Cohen M
Rev Neurol (Paris)
. 2018 Nov;
174(10):722-725.
PMID: 30409479
Introduction: Teriflunomide, a novel, orally bioavailable, active metabolite of leflunomide, has anti-inflammatory activity. It is prescribed as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS) at a dose of one...
5.
Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, et al.
J Neurol
. 2018 Jul;
265(10):2251-2259.
PMID: 30054790
Background: Tumefactive demyelinating lesions of the central nervous system can be the initial presentation in various pathological entities [multiple sclerosis (the most common), Balo's concentric sclerosis, Schilder's disease and acute...
6.
Lebrun C, De Seze J
Rev Neurol (Paris)
. 2018 Jun;
174(6):355.
PMID: 29903398
No abstract available.
7.
8.
Cochen De Cock V, Dotov D, Ihalainen P, Begel V, Galtier F, Lebrun C, et al.
NPJ Parkinsons Dis
. 2018 Mar;
4:8.
PMID: 29582000
Rhythmic auditory cues can immediately improve gait in Parkinson's disease. However, this effect varies considerably across patients. The factors associated with this individual variability are not known to date. Patients'...
9.
Brier S, Le Mignon M, Jain K, Lebrun C, Peurois F, Kellenberger C, et al.
Allergy
. 2017 Nov;
73(5):1032-1040.
PMID: 29171882
Background: Accurate allergen quantification is needed to document the consistency of allergen extracts used for immunotherapy. Herein, we characterize the epitope specificities of two monoclonal antibodies used in an ELISA...
10.
Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, et al.
J Neurol Sci
. 2017 Jan;
373:335-338.
PMID: 28131216
Background: Rituximab (RTX) is increasingly used in the treatment of neuromyelitis optica spectrum disorder (NMO-SD). Administration regimen is not consensual as there is no reliable biomarker of RTX efficacy. In...